Dr. Ruchika Talwar

So as we wrap up here, what are your big takeaways for the audience, people who are listening who may not routinely recommend active surveillance for intermediate risk patients?

What's your message to them?

Yeah.

But you know what?

I'm so glad we're even talking about this because a decade ago, active surveillance in general, let alone for intermediate risk patients, it was like out of the question.

So we've come a long way.

I am excited to see where the field goes.

And I'm really thankful that you spent some time sharing your expertise with us.

Thank you so much for having me.

And to our audience, thanks for joining us.

We hope you'll tune in next time.

Thank you so much for listening.

If you haven't already, make sure to subscribe, rate the podcast five stars, and share with a friend.

If you have any questions or comments, DM us at underscore Backtable Euro on Instagram, LinkedIn, or X. Backtable is hosted by myself, Ruchika Talwar.

And Suzette Sutherland.